Kaitlyn E Egan1, Gregory M Caldwell2, Maxim S Eckmann2. 1. Department of Physical Medicine & Rehabilitation, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas, USA. egank@uthscsa.edu. 2. Department of Anesthesiology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas, USA.
Abstract
PURPOSE OF REVIEW: This article is a systematic review of data from 2018 to 2020 regarding information from publications on epidemiologic, diagnostic, and therapeutic advancements in human immunodeficiency virus-associated peripheral neuropathy. RECENT FINDINGS: The epidemiology/pathology of HIV neuropathy is discussed. Diagnostics includes skin wrinkling-eutectic mixture of local anesthetic test and neurologic examinations. Therapeutic interventions include pharmacologic and nonpharmacologic management as well as self-management strategies. Peripheral neuropathy continues to affect the lives of persons living with HIV. First-line treatment with pregabalin or gabapentin for HIV neuropathic pain has limited data on adequate response. Exercise and self-management strategies may provide benefit in pain reduction. Continuing research on risk factors and biomarkers for HIV-related peripheral neuropathy will be critical for future diagnostic and therapeutic agents.
PURPOSE OF REVIEW: This article is a systematic review of data from 2018 to 2020 regarding information from publications on epidemiologic, diagnostic, and therapeutic advancements in human immunodeficiency virus-associated peripheral neuropathy. RECENT FINDINGS: The epidemiology/pathology of HIV neuropathy is discussed. Diagnostics includes skin wrinkling-eutectic mixture of local anesthetic test and neurologic examinations. Therapeutic interventions include pharmacologic and nonpharmacologic management as well as self-management strategies. Peripheral neuropathy continues to affect the lives of persons living with HIV. First-line treatment with pregabalin or gabapentin for HIV neuropathic pain has limited data on adequate response. Exercise and self-management strategies may provide benefit in pain reduction. Continuing research on risk factors and biomarkers for HIV-related peripheral neuropathy will be critical for future diagnostic and therapeutic agents.
Entities:
Keywords:
HIV; Human immunodeficiency virus; Neuropathic; Neuropathy; Pain; Treatment
Authors: K Hahn; G Arendt; J S Braun; H-J von Giesen; I W Husstedt; M Maschke; M E Straube; E Schielke Journal: J Neurol Date: 2004-10 Impact factor: 4.849
Authors: Scott R Evans; Ronald J Ellis; Huichao Chen; Tzu-min Yeh; Anthony J Lee; Giovanni Schifitto; Kunling Wu; Ronald J Bosch; Justin C McArthur; David M Simpson; David B Clifford Journal: AIDS Date: 2011-04-24 Impact factor: 4.177
Authors: Kristine M Erlandson; Long Zhang; Derek K Ng; Keri N Althoff; Frank J Palella; Lawrence A Kingsley; Lisa P Jacobson; Joseph B Margolick; Jordan E Lake; Todd T Brown Journal: J Acquir Immune Defic Syndr Date: 2019-08-01 Impact factor: 3.731
Authors: D M Simpson; J C McArthur; R Olney; D Clifford; Y So; D Ross; B J Baird; P Barrett; A E Hammer Journal: Neurology Date: 2003-05-13 Impact factor: 9.910
Authors: Jennifer S Gewandter; Christopher H Gibbons; Marta Campagnolo; Joonho Lee; Jenna Chaudari; Nam Ward; Laurie Burke; Guido Cavaletti; David N Herrmann; Justin C McArthur; James W Russell; A Gordon Smith; Shannon M Smith; Dennis C Turk; Robert H Dworkin; Roy Freeman Journal: Neurology Date: 2019-07-18 Impact factor: 9.910
Authors: Cristina Martín-Escura; Alicia Medina-Peris; Luke A Spear; Roberto de la Torre Martínez; Luis A Olivos-Oré; María Victoria Barahona; Sara González-Rodríguez; Gregorio Fernández-Ballester; Asia Fernández-Carvajal; Antonio R Artalejo; Antonio Ferrer-Montiel; Rosario González-Muñiz Journal: Int J Mol Sci Date: 2022-02-28 Impact factor: 5.923